28042600|t|Efficacy of Synbiotics for Treatment of Bacillary Dysentery in Children: A Double-Blind, Randomized, Placebo-Controlled Study
28042600|a|Bacillary dysentery is a major cause of children's admission to hospitals. To assess the probiotic and prebiotic (synbiotics) effects in children with dysentery in a randomized clinical trial, 200 children with dysentery were studied in 2 groups: the synbiotic group received 1 tablet /day of synbiotic for 3-5 days and the placebo group received placebo tablets (identical tablet form like probiotics). The standard treatment was administered for all patients. Duration of hospitalization, dysentery, fever, and the weight loss were assessed in each group. It was concluded that there was no significant difference in both groups in the baseline characteristics. The mean duration of dysentery reduced (P < 0.05). The mean duration of fever has been significantly reduced in the synbiotic group (1.64 ± 0.87 days) in comparison to the placebo group (2.13 ± 0.94 days) (P < 0.001). Average amount of weight loss was significantly lower in the synbiotic group in comparison to that in the placebo group (129.5 ± 23.388 grams and 278 ± 28.385 grams, resp.; P < 0.001). There was no significant difference in the mean duration of hospitalization in both groups (P > 0.05). The use of synbiotics as an adjuvant therapy to the standard treatment of dysentery significantly reduces the duration of dysentery, fever, and rate of weight losses. The trial is registered with IRCT201109267647N1.
28042600	0	8	Efficacy	T080	C1280519
28042600	12	22	Synbiotics	T168	C2936470
28042600	27	36	Treatment	T061	C0087111
28042600	40	59	Bacillary Dysentery	T047	C1527298
28042600	63	71	Children	T100	C0008059
28042600	75	87	Double-Blind	T062	C0013072
28042600	89	99	Randomized	T062	C0206035
28042600	101	125	Placebo-Controlled Study	T062,T170	C0599724
28042600	126	145	Bacillary dysentery	T047	C1527298
28042600	166	176	children's	T100	C0008059
28042600	177	199	admission to hospitals	T058	C0184666
28042600	204	210	assess	T058	C0184514
28042600	215	224	probiotic	T007	C0525033
28042600	229	238	prebiotic	T109	C2717875
28042600	240	250	synbiotics	T168	C2936470
28042600	252	259	effects	T080	C1280500
28042600	263	271	children	T100	C0008059
28042600	277	286	dysentery	T047	C0013369
28042600	292	317	randomized clinical trial	T062,T170	C0206034
28042600	323	331	children	T100	C0008059
28042600	337	346	dysentery	T047	C0013369
28042600	365	371	groups	T078	C0441833
28042600	377	386	synbiotic	T168	C2936470
28042600	387	392	group	T078	C0441833
28042600	404	410	tablet	T122	C0039225
28042600	411	415	/day	T079	C0439505
28042600	419	428	synbiotic	T168	C2936470
28042600	437	441	days	T079	C0439228
28042600	450	457	placebo	T122	C1696465
28042600	458	463	group	T078	C0441833
28042600	473	480	placebo	T122	C1696465
28042600	481	488	tablets	T122	C0039225
28042600	500	506	tablet	T122	C0039225
28042600	517	527	probiotics	T007	C0525033
28042600	534	542	standard	T080	C1442989
28042600	543	552	treatment	T061	C0087111
28042600	557	569	administered	T169	C1521801
28042600	578	586	patients	T101	C0030705
28042600	588	596	Duration	T079	C0449238
28042600	600	615	hospitalization	T058	C0019993
28042600	617	626	dysentery	T047	C0013369
28042600	628	633	fever	T184	C0015967
28042600	643	654	weight loss	T033	C1262477
28042600	660	668	assessed	T052	C1516048
28042600	677	682	group	T078	C0441833
28042600	716	741	no significant difference	T033	C3842396
28042600	750	756	groups	T078	C0441833
28042600	764	772	baseline	T081	C1442488
28042600	773	788	characteristics	T080	C1521970
28042600	794	807	mean duration	T079	C0449238
28042600	811	820	dysentery	T047	C0013369
28042600	821	828	reduced	T080	C0392756
28042600	845	858	mean duration	T079	C0449238
28042600	862	867	fever	T184	C0015967
28042600	891	898	reduced	T080	C0392756
28042600	906	915	synbiotic	T168	C2936470
28042600	916	921	group	T078	C0441833
28042600	935	939	days	T079	C0439228
28042600	944	954	comparison	T052	C1707455
28042600	962	969	placebo	T122	C1696465
28042600	970	975	group	T078	C0441833
28042600	989	993	days	T079	C0439228
28042600	1008	1022	Average amount	T081	C1265611
28042600	1026	1037	weight loss	T033	C1262477
28042600	1069	1078	synbiotic	T168	C2936470
28042600	1079	1084	group	T078	C0441833
28042600	1088	1098	comparison	T052	C1707455
28042600	1114	1121	placebo	T122	C1696465
28042600	1122	1127	group	T078	C0441833
28042600	1203	1228	no significant difference	T033	C3842396
28042600	1236	1249	mean duration	T079	C0449238
28042600	1253	1268	hospitalization	T058	C0019993
28042600	1277	1283	groups	T078	C0441833
28042600	1307	1317	synbiotics	T168	C2936470
28042600	1324	1340	adjuvant therapy	T061	C0677850
28042600	1348	1356	standard	T080	C1442989
28042600	1357	1366	treatment	T061	C0087111
28042600	1370	1379	dysentery	T047	C0013369
28042600	1394	1401	reduces	T080	C0392756
28042600	1406	1414	duration	T079	C0449238
28042600	1418	1427	dysentery	T047	C0013369
28042600	1429	1434	fever	T184	C0015967
28042600	1440	1461	rate of weight losses	T033	C1262477
28042600	1467	1472	trial	T062	C0008976
28042600	1476	1486	registered	T058	C1514821